SCHEMBL12371619

SCHEMBL12371619

CNC(=O)COc1ccc(C=O)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
ROCK2 O75116 1/20 0.55
ROCK1 Q13464 1/20 0.55
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.46
MAOB P27338 2/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
LY96 Q9Y6Y9 1/20 0.45
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
RAPGEF3 O95398 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15331330 0.89 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2ROCK2ROCK1RAB9A
SCHEMBL7682529 0.86 ALDH1A1 (0.61) ALDH1A1ROCK2ROCK1RAB9AKDM4E
SCHEMBL4529316 0.85 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2ROCK2ROCK1MAOB
SCHEMBL3292757 0.84 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2ROCK2ROCK1MAOB
SCHEMBL29669441 0.84 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2ROCK2ROCK1MAOB
SCHEMBL2562580 0.83 ALDH1A1 (0.61) ALDH1A1ROCK2ROCK1RAB9AKDM4E
SCHEMBL17967806 0.83 BCHE (0.48) ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL15329886 0.83 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2ROCK2ROCK1RAB9A
SCHEMBL14455038 0.82 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2RAB9AKDM4ENPC1
SCHEMBL2649087 0.81 MEN1 (0.65) ALDH1A1SMN1; SMN2ROCK2ROCK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
US-20110046131-A1 PURINES AS PKC-THETA INHIBITORS N.V. Organon and Pharmacopeia, LLC 2011-02-24 US disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PRKCE, PRKCH, PRKCQ ALDH1A1 2893/4885SMN1; SMN2 4308/4885ROCK2 102/4885
US-20110046131-A1 PURINES AS PKC-THETA INHIBITORS PRKCQ, PRKCE, PRKCH ALDH1A1 4413/4885SMN1; SMN2 4594/4885ROCK2 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.